170 related articles for article (PubMed ID: 37998793)
1. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016-2020.
Piérard D; Hermsen ED; Kantecki M; Arhin FF
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998793
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of aztreonam-avibactam and comparators against Metallo-β-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016-2020.
Rossolini GM; Arhin FF; Kantecki M
J Glob Antimicrob Resist; 2024 Mar; 36():123-131. PubMed ID: 38154750
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019.
Rossolini GM; Stone G; Kantecki M; Arhin FF
J Glob Antimicrob Resist; 2022 Sep; 30():214-221. PubMed ID: 35760303
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
[TBL] [Abstract][Full Text] [Related]
5.
Wang W; Huang S; Zou C; Ding Y; Wang H; Pu S; Liao Y; Du H; Wang D; Chen L; Niu S
Front Cell Infect Microbiol; 2021; 11():755763. PubMed ID: 34778107
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales.
Kelley CJ; Kennedy-Mendez A; Walser ON; Thwaites MT; Arhin FF; Pillar CM; Hufnagel DA
Microbiol Spectr; 2022 Dec; 10(6):e0360122. PubMed ID: 36342288
[TBL] [Abstract][Full Text] [Related]
7.
Chen J; Liu Y; Jia W; Xu X; Sun G; Wang T; Li J; Zhang G; Jing R; Sun H; Xu Y; Liu Y
Microbiol Spectr; 2023 Jun; 11(3):e0487322. PubMed ID: 37184411
[TBL] [Abstract][Full Text] [Related]
8.
Huang YS; Chen PY; Chou PC; Wang JT
Microbiol Spectr; 2023 Jun; 11(3):e0056923. PubMed ID: 37154758
[TBL] [Abstract][Full Text] [Related]
9. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
Sader HS; Mendes RE; Carvalhaes CG; Kimbrough JH; Castanheira M
Open Forum Infect Dis; 2023 Feb; 10(2):ofad046. PubMed ID: 36846612
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018.
Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971
[TBL] [Abstract][Full Text] [Related]
11. Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant
Sun S; Chen K; Kong X; Tian W; Niu S
Infect Drug Resist; 2022; 15():2243-2251. PubMed ID: 35510161
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Castanheira M
Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):477-487. PubMed ID: 35041100
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of aztreonam/avibactam against a global collection of Klebsiella pneumoniae collected from defined culture sources in 2016 and 2017.
Esposito S; Stone GG; Papaparaskevas J
J Glob Antimicrob Resist; 2021 Mar; 24():14-22. PubMed ID: 32841721
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017).
Rossolini GM; Stone GG
Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602
[TBL] [Abstract][Full Text] [Related]
15. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020.
Karlowsky JA; Bouchillon SK; Benaouda A; Soraa N; Zerouali K; Mohamed N; Alami T; Sahm DF
J Glob Antimicrob Resist; 2022 Sep; 30():23-30. PubMed ID: 35447385
[TBL] [Abstract][Full Text] [Related]
17. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection.
Rawson TM; Brzeska-Trafny I; Maxfield R; Almeida M; Gilchrist M; Gonzalo X; Moore LS; Donaldson H; Davies F
J Glob Antimicrob Resist; 2022 Jun; 29():558-562. PubMed ID: 35131508
[TBL] [Abstract][Full Text] [Related]
18.
Cervino I; Gonzalez D; Nastro M; Vega J; Reyes AP; Buriano G; Vay C; Famiglietti A; Rodriguez CH
J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34605763
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators Against Fluoroquinolone-Resistant
Kiratisin P; Arhin FF; Stone G; Utt E
Microb Drug Resist; 2022 Nov; 28(11):1019-1027. PubMed ID: 36251881
[TBL] [Abstract][Full Text] [Related]
20. In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant
Zou C; Wei J; Shan B; Chen X; Wang D; Niu S
Infect Drug Resist; 2020; 13():3563-3568. PubMed ID: 33116675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
